

In the claims

Please amend claims 1-6, 9-11, 13-16, 18-20 and 22 and add new claim 25 as follows:

(For the Examiner's convenience all the pending claims, 1-7, 9-11 and 13-25 are reproduced in full below)

1. (Twice amended) A composition for inducing an immune response, comprising micelles or micro-aggregates wherein each micelle or micro-aggregate comprises:
a first lipopeptide comprising at least one CTL antigenic determinant and at least one lipid unit, and
a second lipopeptide comprising at least one helper T antigenic determinant and at least one lipid unit.

2. (Twice amended) A composition according to claim 1 wherein the first and second lipopeptides each comprise one or more C₄-C₁₈ lipid units.

3. (Twice amended) A composition according to Claim 1 wherein the first and second lipopeptides each comprise one or two C₄-C₁₈ lipid chains linked by a covalent bond to one or two amino acids of the respective lipopeptide.

4. (Twice amended) A composition according to Claim 1 wherein the lipid units of the lipopeptides each comprise two palmitic acid chains linked to a lysine through an NH₂ group of said lysine.

5. (Twice amended) A composition according Claim 1 wherein the lipid units of each lipopeptide comprises one or more of: a residue of palmitic acid, 2-aminohexadecanoic

acid, oleic acid, linoleic acid, linolenic acid, pimelautide, trimexautide, or a derivative of cholesterol.

D2 6. (Twice amended) A composition according to Claim 1 wherein the non-lipid part of the each of the first and second lipopeptides comprises between 10 and 100 amino acids.

7. A composition according to Claim 1 wherein the helper T antigenic determinant is a multivalent antigenic determinant.

9. (Twice amended) A composition according to Claim 1 wherein the helper T antigenic determinant comprises the antigenic determinant of hemagglutinin or the PADRE antigenic determinant.

D3 10. (Twice amended) A composition according to Claim 1 wherein the lipopeptides comprise at least one CTL antigenic determinant selected from the group consisting of a specific protein of melanoma, a protein from HIV, a protein from HBV, a protein from papillomavirus, protein p53 and a specific protein of *Plasmodium falciparum*.

11. (Twice amended) A composition according to Claim 1 wherein said micelles or micro-aggregates comprise one or more of the following lipopeptides:

GAG 17 EKIRLRPGGKKKYKLKHIVK(Pam)-NH₂ (SEQ ID No: 31)

GAG 253 NPPIPVGEIYKRWIILGLNKIVRMYSPTSILDK(Pam)-NH₂ (SEQ ID No: 6)

POL 325 AIFQSSMTKILEPFRKQNPDIVIYQYMDDLYK(Pam)-NH₂ (SEQ ID No: 32)

NEF 66 VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLK(Pam)-NH₂ (SEQ ID No: 2)

NEF 116 HTQGYFPDWQNYTPGPGVRYPLTFGWLYKLK(Pam)-NH₂ (SEQ ID No: 33)

TT Ac-QYIKANSKFIGITELKKK(Pam)-NH₂ (SEQ ID No: 30).

13. (Twice amended) A method for the production of a vaccine for inducing an immune response comprising micelles or aggregates according to Claim 1.

14. (Twice amended) A method according to Claim 13, said immune response being induced against HIV, HBV, papilloma virus, p53, melanoma, or *Plasmodium falciparum*.

D4 15. (Twice amended) A pharmaceutical composition comprising a pharmacologically effective dose of micelles or micro-aggregates according to Claim 1 and a pharmaceutically compatible vehicle.

16. (Twice amended) A vaccine comprising micelles or micro-aggregates according to Claim 1 and a physiologically acceptable vehicle.

17. A method for producing micelles or micro-aggregates according to Claim 1, comprising the following steps:

- dispersing each of the constituent lipopeptides in a solution of concentrated acetic acid of about 80% concentration then
- mixing the solutions thus obtained.

18. (Twice amended) A method according to Claim 17 wherein the dispersing of the lipopeptides dissolved in acetic acid is confirmed by a two-dimensional nuclear magnetic resonance method.

19. (Twice amended) A method for inducing an immune response against a particular antigen in an individual comprising administering micelles or micro-aggregates according to Claim 1 to the individual.

20. (Twice amended) A method of immunizing an individual against a pathogenic agent comprising the administration of micelles or micro-aggregates according to Claim 1 to the individual.

DS 21. A method according to Claim 19, wherein the pathogenic agent is HIV, HBV, papillomavirus, melanoma or *plasmodium falciparum*, and wherein the antigen is an antigen of one of said pathogenic agents, or p53.

22. (Twice amended) A composition according to Claim 1, wherein the at least one lipid unit in the second lipopeptide is different from any lipid unit in the first lipopeptide.

23. A composition according to Claim 6, wherein the non-lipid part of the lipopeptides, comprising the antigenic determinants, comprises between 10 and 50 amino acids.

24. A method according to Claim 20, wherein the pathogenic agent is HIV, HBV, papillomavirus, melanoma, or *Plasmodium falciparum*, and wherein the antigen is an antigen of one of said pathogenic agents, or p53.

25. (New) A composition according to Claim 8, wherein the helper T antigenic determinant is the peptide 830-843 of the tetanus toxin with the following sequence:

QYIKANSKFIGITE (SEQ ID No: 1).